Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2010 Nov 30.
Published in final edited form as: J Nat Prod. 2009 Nov;72(11):1949–1953. doi: 10.1021/np900572g

Bioactive Constituents of the Stem Bark of Mitrephora glabra

Chen Li 1,†,, Dongho Lee 1,†,§, Tyler N Graf 1,†,, Sharnelle S Phifer 1,, Yuka Nakanishi 1,, Soedarsono Riswan 1,, Fransisca M Setyowati 1,, Achmad M Saribi 1,||, Djaja D Soejarto 1,, Norman R Farnsworth 1,, Joseph O Falkinham III 1,, David J Kroll 1,†,#, A Douglas Kinghorn 1,±, Mansukh C Wani 1,, Nicholas H Oberlies 1,*,†,
PMCID: PMC2862477  NIHMSID: NIHMS156423  PMID: 19874044

Abstract

Bioactivity-guided fractionation of the stem bark of Mitrephora glabra yielded nine compounds, comprising three ent-kaurenoids (1–3), five polyacetylenic acids/esters (4–8), and one aporphine alkaloid, liriodenine (9). The structures of the six new compounds (1–3, 5, 7, and 8) were determined by spectroscopic data interpretation. All compounds were evaluated for their inhibitory activities against a panel of cancer cell lines and a battery of microorganisms.


Over the last two decades, plants of the Annonaceae have been investigated rather extensively, largely for the presence of cytotoxic and/or insecticidal acetogenins.1 Of these natural product-based investigations, however, the genus Mitrephora is relatively under-explored, probably because Annonaceous acetogenins have not been discovered therein, at least to date. There are nearly 50 described species of Mitrephora, and although a few species are relatively widespread in its native range, which extends from mainland China in the north to India in the west to Australia in the southeast, most of these shrubs and small to large trees have very narrow to localized distributions.24 Representatives of such ecological niches may yield secondary metabolites of unique structures; yet, to the best of our knowledge, only five species of Mitrephora have been investigated for bioactive secondary metabolites, specifically, M. celebica,5,6 M. maingayi,79 M. thorelii,10,11 M. tomentosa,12 and M. zippeliana.13

In an ongoing study of potential anticancer agents from the plant kingdom,14,15 an investigation of the constituents of the stem bark of Mitrephora glabra Scheff. (Annonaceae), collected in Indonesia, has been conducted. In an earlier communication, we reported from this plant three new ent-trachylobane diterpenoids, mitrephorenones AC, of which one was shown to possess an unusual oxetane ring, making it the first hexacyclic representative of this compound class.16 A more comprehensive investigation of this species, with the aim of isolating more potent cytotoxic constituents led to the isolation and elucidation of six additional new compounds (1–3, 5, 7, and 8) and three known substances (4, 6, 9). These can be subdivided into three ent-kaurane diterpenoids (1–3) and five polyacetylenic acids/esters (4–8). The known alkaloid, liriodenine (9), for which the structural data were in good agreement with those in the literature,17,18 was isolated as well. This alkaloid was reported recently from M. maingayi9 and may be common to species in the Mitrephora genus; it has been found in at least two other genera of the Annonaceae as well.17 Along with testing in cytotoxicity assays, all compounds were evaluated for antimicrobial activity, largely due to the literature precedence for antimicrobial constituents from this genus.5,6

Results and Discussion

Compound 1 exhibited a molecular formula of C20H30O2, as deduced from HREIMS and 1D NMR data, suggesting an index of hydrogen deficiency of six. An examination of the literature quickly led to the known compound kaurenic acid,19 which has both the same molecular formula and similar NMR data to those of 119(Table 1). COSY, HMBC, and 13C NMR analyses confirmed that compound 1 shares the same planar structure as kaurenic acid. In particular, key resonances were evident at δC 44.3, 36.9, and 103.0, corresponding to positions C-13, C-14, and C-17, respectively. However, the chemical shifts for C-4 (δC 47.6) and C-18 (δC 16.1) were distinctly different than those reported for kaurenic acid,19 suggesting that compound 1 possesses an opposite configuration at C-4. Indeed, this was supported by comparing the chemical shifts of related ent-kaurane and ent-trachylobane diterpenoids, where a methyl in the β configuration results in resonances of approximately δC 44 and δC 29 for positions C-4 and C-18, respectively, as was observed for kaurenic and grandiflorenic acids,19 ent-trachyloban-19-oic acid,20 and 15-oxo-(−)-ent-trachyloban-19-oic acid,21 as opposed to resonances of approximately δC 47 and δC 16 when the methyl was in the α configuration for the same positions in ent-trachyloban-18-oic acid.20 In further support for the C-18 methyl group of 1 being in the α configuration, H3-18 and H3-20 were found to be syn to one another, as measured via a strong ROESY correlation between these resonances. This compound was ascribed the trivial name, 4-epi-kaurenic acid, demonstrating its close similarity to kaurenic acid.

Table 1.

NMR Data for Compounds 1–3 in CDCl3

position 4-epi-kaurenic acid (1) mitrekaurenone (2) methylmitrekaurenate (3)

δC δH (mult.; J in Hz) δC δH (mult.; J in Hz) HMBC δC δH (mult.; J in Hz) HMBC
1 39.5 1.84 (brd; 13); 0.87 (ddd;13, 13, 4) 34.7 1.58 (m)
1.04 (m)
2, 3, 5, 10, 20
2, 3, 9, 10, 20
34.9 1.73 (m) 2, 3, 4
2 18.0 1.58 (m) 18.0 1.56 (m) 1, 3, 4 19.7 1.83 (m); 1.73 (m) 3, 4, 10
3 39.8 1.97 (dd; 12, 3); 1.10 (dd; 12, 5) 29.0 2.22 (ddd; 14, 6, 6)
1.42 (m)
1, 2, 4, 5, 19
1, 2, 4, 18, 19
33.6 2.21 (m); 1.26 (m) 4, 5, 18, 19
4 47.6 --- 41.7 --- -- 44.5 --- ---
5 50.1 1.68 (m) 52.8 2.25 (d; 7.0) 4, 9, 10, 18, 19, 20 59.3 2.65 (s) 4, 6, 9, 10, 18, 19, 20
6 23.2 1.19 (m) 76.6 4.86 (d; 7.0) 7, 8, 10 177.0 --- ---
7 33.2 1.66 (m); 1.51 (m) 209.1 -- -- 183.8 --- ---
8 43.9 --- 53.9 -- -- 52.9 --- ---
9 56.0 1.18 (m) 57.3 1.66 (m) 5, 10, 11, 12, 15, 20 47.6 2.45 (brd; 7) 1, 5, 8, 10, 12, 14
10 38.6 --- 35.5 -- -- 42.8 --- ---
11 40.6 1.58 (m) 31.9 2.11 (m)
1.40 (m)
9, 12, 13
8, 12, 13, 14
32.1 1.81 (m); 1.50 (m) 8, 9
12 17.7 1.62 (m); 1.46 (m) 17.1 1.40 (m)
1.25 (m)
9, 16
9, 11, 13, 14
18.3 1.82 (m); 1.61 (m) 9, 16
13 44.3 2.64 (brs) 37.5 2.71 (brdd; 8.5, 5.5) 8, 11, 12, 15, 16, 17 43.8 2.77 (brs) ---
14 36.9 1.76 (m); 1.62 (m) 32.1 1.98 (dd; 12.0, 5.5)
1.63 (dd; 12.0, 4.0)
7, 8, 9, 11, 12, 13, 15
7, 8, 10, 11, 12, 15, 16
34.2 1.94 (dd; 11, 5); 1.81 (brd; 11) 7, 8, 9, 13
15 49.0 2.09 (d; 15); 2.06 (d; 15) 48.2 2.36 (d; 15)
2.27 (d; 15)
9, 13, 14, 16
9, 16
46.8 2.62 (d; 18); 2.49 (d; 18) 8, 9, 14, 16
16 155.8 --- 156.9 -- -- 152.4 --- ---
17 103.0 4.80 (s); 4.74 (s) 108.3 5.06 (s); 4.90 (s) 13, 15 104.1 4.87 (s); 4.78 (s) 13, 15, 16
18 16.1 1.17 (s) 26.6 1.32 (s) 3, 4, 5, 19 29.1 1.37 (s) 3, 4, 5, 19
19 185.4 --- 180.0 -- -- 178.5 --- ---
20 17.8 1.06 (s) 15.8 0.71 (s) 1, 5, 9, 10 19.1 1.20 (s) 1, 5, 9, 10
OMe 52.3 3.71 (s) 19

The spectroscopic and spectrometric data for compound 2 (C20H26O3; index of hydrogen deficiency of eight) were similar to those of 1, suggesting a structural relationship. For example, the bicyclic C-ring portion of the molecule was intact, as evident from the COSY and HMBC data. However, comparison of the DEPT and 13C NMR data between these compounds (Table 1) revealed some key differences, including the replacement of the C-7 and C-6 methylene units in 1 with a ketone moiety (δC 209.1) and a downfield shifted methine (δC 76.6), respectively, in 2. Both methylene protons on C-14 displayed HMBC correlations with the ketone carbonyl (C-7). The H-6 resonance had HMBC correlations with C-7, C-8, and C-10, suggesting its position adjacent to the ketone. Moreover, the downfield chemical shift of this signal (δH/δC 4.86/76.6) indicated further oxygenation, which was satisfied by an ester linkage between C-6 and C-19. This was supported by the upfield chemical shift of C-19, from δC 185.4 as the free acid in 1 to δC 180.0 as the cyclic ester in 2; this new lactone moiety added another degree of unsaturation, satisfying the index of hydrogen deficiency of eight. The complete HMBC data set (Table 1) was supportive of the structure of this compound being assigned as 2. This compound was described previously as an intermediate in a synthetic degradation experiment;22 however, its physical properties were not reported. To the best of our knowledge, it has not been described previously as a natural product. Therefore, we ascribed the trivial name mitrekaurenone to 2 as a new natural product.

Analysis of 1H and 13C NMR data for compound 3 revealed resonances that were characteristic for portions of the ent-kaurane ring system (C-8 through C-17), consistent with compounds 1 and 2. Three carbonyl moieties were evident from the 13C and DEPT NMR data (Table 1), and one of these was assigned as a methyl ester due to the HMBC from δH 3.71 to δC 178.5 (C-19). Examination of these data in light of the molecular formula information from the HRMALDITOFMS (C21H30O6; index of hydrogen deficiency of seven) revealed at least two exchangeable protons, supportive of the other two carbonyls being carboxylic acids (C-6 and C-7). COSY and HMBC data enabled the assignment of an aliphatic chain comprised of methylene units C-1, C-2, and C-3; HMBC correlations were used to position C-4, C-18, and C-19 to this chain (Table 1). The H3-20 signal displayed HMBC correlations with C-1, C-5, C-9, and C-10, while H3-18 correlated with C-3, C-4, C-5, and C-19. Using these data in conjunction with the HMBC correlations of a methine singlet proton (δH 2.65; H-5) to C-4, C-9, C-10 C-18, C-19, and C-20 permitted the assignment of the A-ring. The H-5 resonance also displayed a HMBC correlation with one of the carboxylic acid moieties, which was placed at C-6 (δC 177.0). The remaining carboxylic acid was positioned at C-7, largely due to a key HMBC correlation from H2-14, finalizing the structure of 3 as a ring B C-6, C-7-seco ent-kaurane diterpenoid. ROESY data revealed correlations of H-5 with both H-9 and H3-18, but not with H3-20, suggesting the relative configurations of positions 4, 5, 9, and 10. Although no direct evidence was obtained from ROESY data for the stereochemical assignments for C-8 and C-13 due to overlapping signals, these two chiral centers were postulated to carry the same configuration as all other known ent-kaurane-type diterpenoids. Therefore, the structure of compound 3 was established as shown and ascribed the trivial name methylmitrekaurenate.

The remaining five compounds (4–8) represented a different structural type than the diterpenoids discussed above. Two of these were known compounds. NMR data for compound 4 revealed the presence of a monosubstituted olefinic unit, a carboxylic acid unit, an aliphatic chain, and three triple bonds, as evidenced from the characteristic signals in the 13C NMR spectrum. These data matched those of the polyacetylenic acid, oropheic acid,23 which was isolated initially from Orophea enneandra and later obtained from Mitrephora celebica.5 The 1H and 13C NMR data indicated that 6 has the same number of carbons as 4, but the terminal double bond was absent, apparent in the chemical shift data for positions 17 and 18 (data not shown). This was in agreement with the HREIMS and molecular formula data, which showed that 6 has two more protons and one less degree of unsaturation than 4. Compound 6 was reported in 2007 from the roots of Polyalthia cerasoides (also a member of the Annonaceae) and named octadeca-9,11,13-triynoic acid;24 our structural data were in agreement with spectroscopic values reported previously.24

Compound 5 gave a molecular formula of C19H24O2, as deduced from HRCIMS data. Its spectroscopic data were very similar to those of 4, and the major difference was the presence of a methyl ester unit (δHC 3.67/51.5) in 5, which had an HMBC correlation to C-1. Due to the structural relationship to 4, this new compound was ascribed the trivial name methyloropheate (5).

NMR data for compound 7 indicated a structural relationship with compounds 4 and 5. However, several extra signals were observed in the 13C NMR spectrum, and the molecular formula (C21H26O3 from HRCIMS) suggested the presence of an extra ring or double bond, relative to 4 or 5, to satisfy the index of hydrogen deficiency of nine. Studies of the COSY and coupling constant data revealed a proton spin system comprising H2-1′, H-2′, and H2-3′, and this partial structure was incorporated into the oropheic acid backbone, on the basis of HMBC correlations. For example, H-2′ displayed correlations with C-1 and C-2, while H2-1′ showed correlations with C-1, C-2, and C-3, suggesting a γ-lactone ring; the IR data (1770 cm−1) were supportive of a lactone moiety.25 ROESY experiments were conducted to establish the relative stereochemistry. H-2 correlated with both H2-3′ protons, indicating their syn configuration. This compound was assigned the trivial name oropheolide.

The NMR data of compound 8 were found to be similar to those of 7 (Table 2). Based on the molecular formula (C21H28O3 from HRCIMS), compound 8 gave two more protons and one less degree of hydrogen deficiency than 7. These data were consistent with replacement of one of the triple bond moieties in 7 with a trans double bond in 8 (J value of 15 Hz; Table 2). COSY and HMBC data were examined to verify the position of this double bond. One of the olefinic protons displayed correlations with C-7 and C-8, while the other displayed correlations with C-11 and C-12, supportive of an olefinic unit between positions 9 and 10. The relative configurations at C-2 and C-2′ were presumed to be similar to those observed in compound 7, and 8 was given the trivial name 9,10-dihydrooropheolide.

Table 2.

1H and 13C NMR Data for Compounds 5, 7, and 8 in CDCl3

position methyloropheate (5) oropheolide (7) 9,10-dihydrooropheolide (8)

δC δH (mult.; J in Hz) δC δH (mult.; J in Hz) δC δH (mult.; J in Hz)
1 174.2 --- 179.8 --- 179.4 ---
2 34.1 2.25 (m) 32.1 2.25 (m) 32.7 2.25 (m)
3~6* 28.0~ 29.7 1.35~ 1.55 (m) 27.8~ 29.5 1.35~ 2.03 (m) 27.3~ 28.8 1.35~ 2.03 (m)
7* 24.9 1.53 (m) 27.0 1.53 (m) 29.6 1.53 (m)
8 19.4 2.30 (t; 7) 19.3 2.28 (t; 7) 31.2 2.70 (m)
9 78.3 --- 78.4 --- 147.1 6.27 (dt; 15, 6)
10 65.8 --- 65.7 --- 109.2 5.51 (d; 15)
11 60.7 --- 60.2 --- 83.6 ---
12 60.3 --- 60.5 --- 73.1 ---
13 66.2 --- 66.0 --- 65.4 ---
14 79.4 --- 79.3 --- 74.0 ---
15 19.3 2.38 (t; 7) 19.2 2.38 (t; 7) 19.1 2.38 (t; 7)
16 32.2 2.28 (dd; 14, 7) 31.1 2.30 (m) 32.5 2.30 (m)
17 136.1 5.84 (m) 136.0 5.84 (m) 137.3 5.84 (m)
18 116.2 5.10 (dd; 16, 2)
5.04 (dd; 11, 2)
116.2 5.12 (dd; 16, 2)
5.04 (dd; 11, 2)
115.4 5.12 (dd; 16, 2)
5.04 (dd; 11, 2)
1′ --- --- 39.5 2.70 (m) 39.5 2.70 (m)
2′ --- --- 78.6 4.60 (m) 78.3 4.60 (m)
3′ --- --- 64.4 3.87 (dd; 12, 3)
3.65 (dd; 12, 5)
64.5 3.87 (dd; 12, 3)
3.65 (dd; 12, 5)
OMe 51.5 3.67 (s) --- --- --- ---
*

signals may be interchangeable.

The compounds isolated from M. glabra in the present investigation were examined against a panel of cancer cell lines. Among the ent-kaurane diterpenoids (1–3), all were inactive (IC50 values >10 μM); the diterpenoids of the ent-trachylobane class, reported previously from the same plant, were more potent in this regard.16 The polyacetylenes (4 and 6–8) gave IC50 values ranging from 10 to 40 μM. However, compound 5 was completely inactive, suggesting that the methyl ester diminishes cytotoxicity. The known alkaloid liriodenine (9) was the most cytotoxic against all four of the cell lines in which it was evaluated (IC50 value ~ 5 μM).

Diterpene and polyacetylene compounds have been reported from a related species (M. celebica) to have antibacterial activity.5,6 Modest antimicrobial activity was detected for all the isolated compounds when tested against a microbial panel consisting of bacteria (Micrococcus luteus and Mycobacterium smegmatis), yeast (Saccharomyces cerevisiae), and fungus (Aspergillus niger) (Table 3). Compound 6 was reported previously to have activity against Mycobacterium tuberculosis (MIC of 6.25 μg/mL);24 against a similar organism (M. smegmatis) it displayed a modest MIC value of 25 μg/mL. Antifungal activity in the absence of cytotoxicity, such as was observed for compounds 5 and 8, suggests possible utility as antimicrobial agents for the treatment of human fungal infections.

Table 3.

Antimicrobial Assay Data for Compounds Isolated from M. glabra

compound antimicrobial activity (MIC in μg/mL)a
solution turbidityb M. luteus M. smegmatis S. cerevisiae A. niger
1 clear 50 50 50 100
2 clear 150 38 38 38
3 clear 150 75 150 150
4 clear 94 94 47 188
5 clear 50 12 25 25
6 clear 25 25 25 50
7 turbid 125 31 63 250
8 clear 50 12 12 12
9 clear 6.3 12 12 25
positive controlsc clear 0.1 0.2 25 25
a

Minimal inhibitory concentration (MIC) is the lowest concentration of compound completely inhibiting growth (as turbidity) expressed in μg/mL.27

b

Presence of turbidity or color in compound dissolved in 1 mL EtOH. Presence of turbidity could lead to an over estimation of MIC, because turbidity due to compound would have obscured endpoint (no turbidity due to microbial growth).

c

Average values. Ampicillin was the positive control for M. luteus, kanamycin was the positive control for M. smegmatis, and amphotericin B was the positive control for S. cervisiae and A. niger.

Experimental Section

General Experimental Procedures

Optical rotation, UV, and IR data were acquired on a Rudolph Autopol III polarimeter, a Varian Cary 3 UV-vis spectrophotometer, and a Nicolet Avatar 360 FT-IR, respectively. All NMR experiments were performed in CDCl3 with TMS as an internal standard; gs-COSY, ROESY, gs-HSQC, gs-HMBC and 1H NMR spectra were acquired on a Varian Unity INOVA-500 instrument using a 5 mm broad-band inverse probe with z-gradient, while a Bruker DPX-300 instrument was utilized for some of the 1H, 13C NMR and DEPT-135 NMR spectra using a Bruker 5 mm QNP probe. LRESIMS data were acquired using an API 150EX mass spectrometer (Applied Biosystems; Foster City, CA). HREIMS were performed with a Kratos MS-25 using 70 eV ionization conditions or HREIMS and HRCIMS were performed on a Finnigan MAT 95Q hybrid-sector instrument (ThermoFinnigan; San Jose, CA). HRMALDITOFMS data were acquired with an Applied Biosystems TOF/TOF mass spectrometer (Framingham, MA), equipped with a Nd:YAG laser operating at 355 nm and 200 Hz. This instrument was operated in the reflectron mode, and the matrix employed was 2,5-dihydroxybenzoic acid prepared at a concentration of 9 mg/mL in 70:30 (v:v) acetonitrile-0.1% trifluoroacetic acid. Column chromatography was carried out on silica gel 60 (70–230 mesh, Merck, Darmstadt, Germany), and fractions were monitored via TLC (silica gel 60 F254 plates, 0.25 mm thickness) visualized with vanillin-sulfuric acid in EtOH. Preparative HPLC was carried out on a Varian Prostar HPLC system (Walnut Creek, CA) equipped with Prostar 210 pumps and a 330 photodiode array detector (PDA), with data collected and analyzed using Star Chromatography Workstation software (version 5.52) using an ODS-A column (250 × 25 mm, i.d., 5 μm; YMC, Wilmington, NC). The percent yields of isolated compounds were calculated based on the dry weight of the plant material (w/w).

Plant Material

The bark of Mitrephora glabra Scheff. (Annonaceae) was collected in Kasintu village, Tewah district, Kapuas regency, Central Kalimantan province, Indonesia, in October, 1999. A voucher herbarium specimen (Riswan et al. TWH077) has been deposited at the John G. Searle Herbarium of the Field Museum in Chicago under accession number F-2221275.

Extraction and Isolation

The dried bark (984 g) was extracted in a Soxhlet with hot MeOH (3 L × 2) for 24 h. The extracts were combined, concentrated in vacuo, and diluted with H2O to give a MeOH-H2O (9:1) solution (0.6 L) that was defatted with hexane (0.6 L × 2). The aqueous MeOH fraction was concentrated in vacuo and partitioned between CHCl3-MeOH (4:1, 0.3 L) and H2O (0.3 L × 2). The organic fraction was then washed with 1% saline until there was no evidence of tannins26 and concentrated to afford a crude organic extract (22.8 g). This sample was separated on a flash silica gel column that was developed using a gradient of 100% hexane to 100% CHCl3 to 100% MeOH. The fractions were combined into 13 pools based on TLC properties and examined against the KB assay, and further studies were conducted on the bioactive fractions. An aliquot (170 mg) of pool 5 (ca. 4.4 g), which eluted using 2.8% MeOH in CHCl3, was purified via RP-HPLC (flow rate of 10 mL/min using a gradient of 70% to 90% CH3CN in H2O over 40 min) to yield compounds 1 (16 mg), 2 (8 mg), and 4 (11 mg). Pools 6 and 7 were combined, and then subjected consecutively to another silica gel column using a hexane/ethyl acetate gradient to give 10 sub-fractions (A-1 to A-10). Fraction A-1 (1.8 g) was then subjected to a diol column followed by preparative RP-HPLC (same conditions as above) to yield compounds 3 (10 mg) and 5 (3 mg), while fraction A-5 (1.3 g) was subjected directly to preparative RP-HPLC (same conditions as above) to yield compounds 6 (4 mg), 7 (35 mg), 8 (2 mg), and liriodenine (11 mg).

4-epi-Kaurenic acid (1): colorless oil (16 mg, yield 0.0016% w/w); [α]D -72.1 (c 0.1, CH2Cl2); UV (MeOH) λmax 206 (ε 4434) nm; IR (CH2Cl2) νmax 3063, 2984, 2926, 2864, 1692 cm−1; 1H NMR, 13C NMR, and HMBC data, see Table 1; ESIMS m/z 303 [M + 1]+ (100%); HREIMS m/z 302.2248 [M]+, calcd for [C20H30O2]+ 302.2246.

Mitrekaurenone (2): colorless oil (8 mg, yield 0.0008% w/w); [α]D -2.0 (c 0.1, CH2Cl2); UV (MeOH) λmax 206 (ε 5420), 264 (268), 298 (166) nm; IR (CH2Cl2) νmax 3069, 2948, 2877, 1780, 1717 cm−1; 1H NMR, 13C NMR, and HMBC data, see Table 1; ESIMS m/z 315 [M + 1]+ (100%); HREIMS m/z 314.1884 [M]+, calcd for [C20H26O3]+ 314.1881.

Methylmitrekaurenate (3): colorless oil (10 mg, yield 0.0010% w/w); [α]D -66.8 (c 0.5, CH2Cl2); UV (MeOH) λmax 204 (ε 4647), 278 (511) nm; IR (CH2Cl2) νmax 3061, 2947, 2867, 1736, 1718, 1698 cm−1; 1H NMR, 13C NMR, and HMBC data, see Table 1; ESIMS m/z 379 [M+1]+ (100%); HRMALDITOFMS m/z 379.2115 [M+H]+ and 401.1935 [M + Na]+ (calcd for [C21H30O6 + H]+, 379.2121 and [C21H30O6 + Na]+ 401.1940, respectively).

Methyloropheate (5): colorless oil (3 mg, yield 0.0003% w/w); UV (MeOH) λmax 217 (ε 6678), 240 (673), 253 (633), 266 (666), 281 (625) nm; IR (CH2Cl2) νmax 2935, 2856, 2214, 1736 cm−1; 1H and 13C NMR data, see Table 2; ESIMS m/z 307 [M + Na]+ (100%); HRCIMS m/z 285.1841 [M + H]+, calcd for [C19H24O2 + H]+, 285.1856.

Octadeca-9,11,13-triynoic acid (6): colorless oil (4 mg, yield 0.0004% w/w); UV (MeOH) λmax 216 (ε 6317), 241 (660), 253 (786), 267 (900), 282 (720) nm; IR (CH2Cl2) νmax 2933, 2858, 2211, 1710 cm−1; 1H and 13C NMR data were in good agreement with the literature;24 ESIMS m/z 273 [M + H]+ (100%); HREIMS m/z 272.1780 [M]+, calcd for [C18H24O2]+, 272.1771.

Oropheolide (7): colorless oil (35 mg, yield 0.0036% w/w); [α]D -12.3 (c 1.0, CH2Cl2); UV (MeOH) λmax 217 (ε 1755), 240 (242), 253 (471), 267 (699), 282 (575) nm; IR (CH2Cl2) νmax 3466, 2938, 2856, 2216, 1770 cm−1; 1H and 13C NMR data, see Table 2; selected HMBC data: H-2′ → C-1, C-2; H2-1′ → C-1, 2, 3; H2-7 → C-8, 9; H2-8 → C-9, 10; H2-15 → C-14, 16; H2-16 → C-15, 17, 18; H-17 → C-15, 16, 18; H-18 → C-16, 17; key ROESY data: H-2 → H2-3′; ESIMS m/z 349 [M + Na]+ (100%); HRCIMS m/z 327.1953 [M + H]+, calcd for [C21H26O3 + H]+, 327.1960.

9,10-Dihydrooropheolide (8): colorless oil (2 mg, yield 0.0002% w/w); [α]D -3.0 (c 0.1, CH2Cl2); UV (MeOH) λmax 213 (ε 13890), 240 (1793), 253 (3340), 267 (4845), 281 (625) nm; IR (CH2Cl2) νmax 2933, 2856, 2214, 1773 cm−1; 1H and 13C NMR data, see Table 2; key ROESY data: H-1 → H2-3′; ESIMS m/z 351 [M + Na]+ (100%); HRCIMS m/z 329.2101 [M + H]+, calcd for [C21H28O3 + H]+, 329.2117.

Liriodenine (9): yellow amorphous solid (11 mg, yield 0.0011% w/w); 1H and 13C NMR data were in good agreement with the literature.17,18

Cytotoxicity Assays

The cytotoxicity measurements against the KB human oral epidermoid carcinoma (American Type Culture Collection, Manassas, VA), MCF-7 human breast carcinoma (Barbara A. Karmanos Cancer Center, Detroit, MI), NCI-H460 human large cell lung carcinoma (American Type Culture Collection, Manassas, VA), and SF-268 human astrocytoma (NCI Developmental Therapeutics Program, Frederick, MD) cell lines were performed as described previously with one modification.27 The assay was monitored via absorbance at the optimal UV maxima of 562 nm.

Antimicrobial Assays

Strains of Micrococcus luteus, Mycobacterium smegmatis, Saccharomyces cerevisiae, and Aspergillus niger were grown, and suspensions prepared, as described previously.28 Minimal inhibitory concentrations (MICs) for complete inhibition by pure compounds were measured by broth microdilution in 96-well microtiter dishes as described previously.27

Supplementary Material

1_si_001

Acknowledgments

This investigation was initiated via grant U19-CA52956 and completed via grant P01-CA125066, both from the National Cancer Institute, NIH, Bethesda, Maryland. C. L., D. L., and N. H. O. gratefully acknowledge partial support via a Research Scholar Grant from the American Cancer Society (RSG-02-024-01-CDD). The Golden LEAF Foundation (Rocky Mount, NC) provided partial support to D. J. K. HRMS were acquired by the Mass Spectrometry Research Group at Research Triangle Institute, the Ohio State University Chemistry Mass Spectrometry Facility, and the Mass Spectrometry Core Facility at the University of Florida. We thank Dr. Arlene Sy-Cordero for helpful discussions on this manuscript.

Footnotes

Supporting Information Available: NMR spectra for new compounds (1–3, 5, 7, 8). This information is available free-of-charge via the Internet at http://pubs.acs.org.

References and Notes

  • 1.Alali FQ, Liu XX, McLaughlin JL. J Nat Prod. 1999;62:504–540. doi: 10.1021/np980406d. [DOI] [PubMed] [Google Scholar]
  • 2.Weerasooriya AD, Chalermglin P, Saunders RMK. Nord J Bot. 2006;24:201–206. [Google Scholar]
  • 3.Weerasooriya AD, Saunders RMK. Bot J Linn Soc. 2001;135:305–313. [Google Scholar]
  • 4.Weerasooriya AD, Saunders RMK. Syst Bot. 2005;30:248–262. [Google Scholar]
  • 5.Zgoda JR, Freyer AJ, Killmer LB, Porter JR. J Nat Prod. 2001;64:1348–1349. doi: 10.1021/np0102509. [DOI] [PubMed] [Google Scholar]
  • 6.Zgoda-Pols JR, Freyer AJ, Killmer LB, Porter JR. Fitoterapia. 2002;73:434–438. doi: 10.1016/s0367-326x(02)00124-7. [DOI] [PubMed] [Google Scholar]
  • 7.Lee NH, Xu YJ, Goh SH. J Nat Prod. 1999;62:1158–1159. doi: 10.1021/np980565x. [DOI] [PubMed] [Google Scholar]
  • 8.Yu R, Li BG, Ye Q, Zhang GL. Nat Prod Res. 2005;19:359–362. doi: 10.1080/14786410412331280104. [DOI] [PubMed] [Google Scholar]
  • 9.Deepralard K, Pengsuparp T, Moriyasu M, Kawanishi K, Suttisri R. Biochem Syst Ecol. 2007;35:696–699. [Google Scholar]
  • 10.Ge F, Tang CP, Ye Y. Helv Chim Acta. 2008;91:1023–1030. [Google Scholar]
  • 11.Meng DH, Xu YP, Chen WL, Zou J, Lou LG, Zhao WM. J Asian Nat Prod Res. 2007;9:679–684. doi: 10.1080/10286020601103270. [DOI] [PubMed] [Google Scholar]
  • 12.Supudompol B, Chaowasku T, Kingfang K, Burud K, Wongseripipatana S, Likhitwitayawuid K. Nat Prod Res. 2004;18:387–390. doi: 10.1080/14786410310001643902. [DOI] [PubMed] [Google Scholar]
  • 13.Brophy J, Goldsack R, Forster P. J Essent Oil Res. 2004;16:95–100. [Google Scholar]
  • 14.Kinghorn AD, Farnsworth NR, Soejarto DD, Cordell GA, Swanson SM, Pezzuto JM, Wani MC, Wall ME, Oberlies NH, Kroll DJ, Kramer RA, Rose WC, Vite GD, Fairchild CR, Peterson RW, Wild R. Pharm Biol. 2003;41(Suppl):53–67. [Google Scholar]
  • 15.Kinghorn AD, Carache de Blanco EJ, Chail HB, Orjala J, Farnsworth NR, Soejarto DD, Oberlies NH, Wani MC, Kroll DJ, Pearce CJ, Swanson SM, Kramer RA, Rose WC, Fairchild CR, Vite GD, Emanuel S, Jarjoura D, Cope FO. Pure Appl Chem. 2009;81:1051–1063. doi: 10.1351/PAC-CON-08-10-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Li C, Lee D, Graf TN, Phifer SS, Nakanishi Y, Burgess JP, Riswan S, Setyowati FM, Saribi AM, Soejarto DD, Farnsworth NR, Falkinham JO, III, Kroll DJ, Kinghorn AD, Wani MC, Oberlies NH. Org Lett. 2005;7:5709–5712. doi: 10.1021/ol052498l. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Harrigan GG, Gunatilaka AA, Kingston DGI, Chan GW, Johnson RK. J Nat Prod. 1994;57:68–73. doi: 10.1021/np50103a009. [DOI] [PubMed] [Google Scholar]
  • 18.Guinaudeau H, Lebceuf M, Cave A. J Nat Prod. 1994;57:1033–1135. [Google Scholar]
  • 19.Enriquez RG, Barajas J, Ortiz B, Lough AJ, Reynolds WF, Yu M, Leon I, Gnecco D. Can J Chem. 1997;75:342–347. [Google Scholar]
  • 20.Leong YW, Harrison LJ. Phytochemistry. 1997;45:1457–1459. [Google Scholar]
  • 21.Harrigan GG, Bolzani VD, Gunatilaka AAL, Kingston DGI. Phytochemistry. 1994;36:109–113. [Google Scholar]
  • 22.Cross BE, Galt RHB, Hanson JR. J Chem Soc. 1963:2944–2961. [Google Scholar]
  • 23.Cavin A, Potterat O, Wolfender J, Hostettmann K, Dyatmyko W. J Nat Prod. 1998;61:1497–1501. doi: 10.1021/np980203p. [DOI] [PubMed] [Google Scholar]
  • 24.Kanokmedhakul S, Kanokmedhakul K, Lekphrom R. J Nat Prod. 2007;70:1536–1538. doi: 10.1021/np070293a. [DOI] [PubMed] [Google Scholar]
  • 25.Pretsch E, Clerc T, Seibl J, Simon W. Tables of Spectral Data for Structure Determination of Organic Compounds. 2. Springer-Verlag; Berlin, New York: 1989. pp. I135–I140. [Google Scholar]
  • 26.Wall ME, Wani MC, Brown DM, Fullas F, Oswald JB, Josephson FF, Thornton NM, Pezzuto JM, Beecher CWW, Farnsworth NR, Cordell GA, Kinghorn AD. Phytomedicine. 1996;3:281–285. doi: 10.1016/S0944-7113(96)80067-5. [DOI] [PubMed] [Google Scholar]
  • 27.Alali FQ, El-Elimat T, Li C, Qandil A, Alkofahi A, Tawaha K, Burgess JP, Nakanishi Y, Kroll DJ, Navarro HA, Falkinham JO, III, Wani MC, Oberlies NH. J Nat Prod. 2005;68:173–178. doi: 10.1021/np0496587. [DOI] [PubMed] [Google Scholar]
  • 28.Cain CC, Henry AT, Waldo RH, III, Casida LJ, Jr, Falkinham JO., III Appl Environ Microbiol. 2000;66:4139–4141. doi: 10.1128/aem.66.9.4139-4141.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1_si_001

RESOURCES